Palabra clave
Palabra clave
000 - Bos d 9 (Bos taurus domestic 9 or αS1‐casein) 000 - MASK‐air® 001 - 5-Grass pollen tablet 001 - Adenotonsillar disease 001 - Adherence 002 - Adjuvant 003 - Adolescent 003 - Adrenaline 003 - Adults 004 - Adverse events 005 - Adverse pregnancy outcomes 005 - Adverse reactions 006 - Aeroallergen 007 - Aeroantigen 008 - Airway inflammation 008 - AIT 008 - ALEX multiplex array 008 - Allergen 009 - Allergen carrier 010 - Allergen challenge 010 - Allergen desensitization 011 - Allergen epitopes profiling 011 - Allergen extract 012 - Allergen exposure chamber (AEC) 012 - Allergen immune therapy (AIT) 012 - Allergen immunotherapy 013 - Allergen surveillance 013 - Allergen tolerance 013 - Allergen-specific immunotherapy 014 - Allergenic epitopes 015 - Allergens 015 - Allergens and epitopes 016 - Allergen microarray 016 - Allergen mixtures 016 - Allergen-specific immunotherapy 016 - Allergen‐specific B cells 016 - Allergic rhinoconjunctivitis 017 - Allergen-specific immunotherapy 017 - Allergen-specific prevention of allergy 018 - Allergic 019 - Allergic asthma 019 - Allergic diseases 020 - Allergic lung disease 020 - Allergic march 021 - Allergic reaction 022 - Allergic respiratory diseases 023 - Allergic rhinitis 024 - Allergic rhinoconjunctivitis 025 - Allergic sensitisation 026 - Allergoid 027 - Allergy 027 - AllergyMonitor® 028 - Allergy diagnosis 028 - Allergy immunotherapy 029 - Allergy treatment 029 - Allergy vaccine 030 - Alt a 1 030 - Alternaria 030 - Alternaria alternata 031 - Aluminium hydroxide 032 - Anaphylaxis 033 - Antagomirs 034 - Antibiotics 035 - Antibodies 035 - Antibody responses 036 - Anti-allergic medication 036 - Anti-IgE 036 - Antigens 036 - Antihistamine 036 - Antisense molecules 036 - Antiviral mechanisms 036 - apps 037 - Ara h 2 037 - ARIA 037 - Artificial intelligence 037 - ASIT 038 - Asthma 038 - Asthma mechanisms 038 - Asthma onset 038 - Asthma phenotype 038 -Asthma genetics 039 - Atopic dermatitis 039 - Atopic march 039 - Autoimmune 039 - Autonomy 040 - Avoidance 041 - B-cell 041 - B-cell epitope 041 - BAFF 041 - Baked egg allergy 041 - Baked-milk product 041 - Barrier function 041 - Barriers 041 - Basal serum tryptase 041 - Basic immunology 041 - Basic interest principle 041 - Basic mechanisms 041 - Basophils 042 - Basophil activation 042 - Basophil anergy 043 - Basophil threshold sensitivity 044 - B-cell epitope-based immunotherapy 045 - Bet v 1 045 - Bet v 1-associated food allergy 045- Bee venom allergy 046 - Beneficence 046 - Best interest principle 046 - Big Data 046 - Biologic 046 - Biologic agents 047 - Bibliometric study 047 - Biologicals 047 - Biomarker 047 - Biotherapy 048 - Birch 049 - Birch pollen 049 - Birch pollen-galactomannan conjugate ointment 050 - Birch pollen allergoid 050 - Birch pollen allergy 051 - Blimp1 051 - Blocking antibody 051 - Blocking capacity 052 - Blomia tropicalis 053 - Bootstrap aggregating strategy 053 - BPFA 053 - Bronchial allergen challenge 053 - Bronchial asthma 053 - Bronchial hyperresponsiveness 054 - Buildup phase OIT patterns 055 - Calcium phosphate 056 - Cancer 056 - CAP-inhibition 056 - Capsules 057 - Carbohydrate determinants 057 - Cat allergy 058 - Cashew 058 - Cats 059 - CD203c 059 - CD29 059 - CD4+ T cells 060 - CD63 061 - Cedar pollinosis 061 - Cell epitopes 061 - Central compartment atopic disease 061 - Chamber validation 061 - Child 061 - Childhood 061 - Childhood asthma 061 - Children 061 - China 061 - Chinese herbal therapy 061 - Cholera enterotoxin B 062 - Chronic rhinosinusitis 062 - Chronic rhinosinusitis control 062 - Chronic rhinosinusitis management 062 - Chronic rhinosinusitis questionnaires 062 - Chronic rhinosinusitis symptoms 062 - Chronic sinusitis 062 - Chronotherapy 062 - Circulating blood cells 062 - CiteSpace 062 - Citokine 063 - Cladosporium 064 - Class effect 065 - Clinical development 066 - Clinical efficacy 067 - Clinical endpoint 067 - Clinical evaluation 067 - Clinical immunology 067 - Clinical relevance 067 - Clinical response 067 - Clinical trial 067 - Cluster analysis 067 - Cockroach 067 - Cockroach allergy 068 - Combined score 068 - Combined symptom and medication score 068 - Combined therapy 068 - Component resolved diagnosis 068 - Component-specific antibody 068 - Congenital malformations 069 - Conjunctival provocation test 069 - Conjunctivitis 069 - Consent 069 - Contraindications 070 - Consensus 070 - Conventional OIT 070 - COPs 070 - Correlation 070 - Corticosteroid 071 - Cost 071 - Cost-effectiveness 072 - Cost-saving 073 - Cost analysis 073 - Cost-utility analysis 074 - Cough 074 - COVID-19 074 - Cow’s milk allergy 075 - Cow’s milk protein allergy 076 - Cromolyn 076 - Cross-product comparability 076 - Cross-reactivity 076 - CSU 077 - Cumulative dose 078 - Cumulative reactive dose 079 - Cumulative tolerated dose 079 - CXCL13 079 - Cyclophilins 079 - Cytokine 079 -Cut-off values 080 - Danger signals 080 - Database analysis 081 - Decisional discord 081 - Decongestant 081 - Delivery system 082 - Delphi consensus 082 - Delphi study 082 - Dendritic cells 083 - Dermatitis 083 - Dermatophagoides farinae 084 - Der f 36 084 - Dermatophagoides pteronyssinus 085 - Desensitization 086 - Desensitization state 087 - Development and evaluation 088 - Diagnosis 088 - Diet 088 - Diet Therapy 088 - Dietary advancement therapy 089 - Differential blood count 089 - Digital biomarkers 089 - digital health 090 - DISABKIDS 090 - Discrete choice experiment 090 - Disease‐modifying 090 - Disparities in health care 090 - Disparity 091 - DNA methylation 092 - DNA vaccines 093 - Dog allergen 093 - Dogs 094 - Dose adjustment 094 - Dose response curve 095 - Double sensitization 095 - Double sensitization to vespids 096 - Double-blind, placebo-controlled food challenge 097 - Drugs 097 - Dupilumab 097 - Dust mite 098 - Dust mite allergy 098 - Dust mite extract 098 - Dust mite immunotherapy 098 - E-B-FAHF-2 098 - Early introduction 099 - EAACI 099 - Economics 099 - ECP-MPO test paper 099 - Eczema 099 - Education 099 - Effective egg OIT 099 - Epidemiology 100 - Effectiveness 100 - Effectiveness and safety 100 - Efficacy 100 - Efficacy and safety 101 - Egg 101 - Egg ladder 102 - Egg allergy 103 - Egg consumption 104 - Egg OIT 105 - Egg oral immunotherapy 106 - Elastic net algorithm 107 - Elderly people 107 - Eliciting dose 108 - Emollient 108 - Endpoints 108 - Enteric-coated capsules 109 - Environment 109 - Environmental allergens 109 - Environmental factors 110 - Eosinophilic esophagitis 111 - Epicutaneous 112 - Epicutaneous immunotherapy 112 - Epidemiology 113 - Epigenetic editing 114 - Epigenetics 115 - Epinephrine 116 - Epitope 117 - epithelial barrier 117 - Epithelium 117 - Epitope-specific antibodies 118 - Ethical principles 118 - Ethnic disparities 118 - Evidence-based medicine 118 - Evolution of adverse reactions 118 - Ex vivo 118 - Exacerbations 118 - Exosome 119 - FAB assay 119 - Fc receptor 119 - Fel d 1 120 - Feasibility 120 - Filaggrin 120 - Flow cytometry 121 - Food 122 - Food allergy 122 - Food allergy treatment 122 - Food Allergyen 122 Food allergy prevention 123 - Food aversion 124 - Food challenge 124 - Food hypersensitivity 125 - Food immunotherapy 125 - Food ladder 125 - Food oral immunotherapy 126 - Forkhead protein 3 127 - France 128 - Fungal allergy 128 - Furry animals 128 - Future 128 - Futurism 129 - Gastrointestinal delivery 130 - Gene expression 130 - Gene-targeted therapy 130 - Genetic vaccines 130 - Gibberellin-regulated protein 131 - Grading of recommendations assessment 132 - Grass 132 - Grass allergens 133 - Grass pollen 134 - Grass pollen allergy 135 - Grass pollen peptides 136 - Grass pollen tablet 137 - Guidelines 137 - Hapten–carrier 137 - Harm principle 138 - Hay fever 138 - HDM allergy 138 - HDM SLIT-tablet 139 - Health care quality assurance 139 - Health care resource use 139 - Health-related quality of life 140 - Healthy responses 141 - Hen’s egg 141 - Hen’s egg allergy 142 - Hereditary α-tryptasemia 142 - Home use 142 - House dust mite 142 - House dust mite sublingual immunotherapy 143 - Honeybee venom 143 - House dust mite allergy 144 - Hymenoptera 144 - Hymenoptera allergy 145 - Hymenoptera venom allergy 146 - Hypersensitivity 147 - Hypoallergenic 147 - Hypoallergenic foods 147 - Hypoallergenic vaccine 148 - Hypoallergens 149 - IgA 149 - IgA1 149 - IgA2 149 - IgE 149 - IgE epitope 149 - IgE skin prick test 149 - IgE synthesis 149 - IgE-FAB 149 - IgE‐blocking factor 149 - IgE‐mediated food allergy 150 - IgG 150 - IgG monoclonal antibodies 151 - IgG4 152 - Ignorance 153 - IL-10 153 - Immune cells 153 - Immune dysregulation 154 - Immune mechanisms 154 - Immune modulation 154 - Immune response 154 - Immune signature 154 - Immune system diseases 154 - Immune tolerance 155 - Immunoaging 155 - Immunoglobulin 155 - Immunoglobulin E 155 - Immunoglobulin G4 155 - Immunoinformatics 156 - Immunological parameters 156 - Immunological proteins 156 - Immunology 156 - Immunophenotyping assessment of COVID-19 157 - Immunostimulatory sequences 158 - Immunotherapy 159 - Immunotherapy adverse reactions 159 - Immunotherapy and tolerance induction 159 - Immunotherapy andtolerance induction 159 - Immunotherapy for allergy 159 - Immunotherapy route 159 - Immunotherapy vaccines and mechanisms 160 - Immuno-modulation and regulation 160 - Immunopathologies 160 - In silico 160 - In vivo diagnostics 160 - In-house reference preparation 160 - Infants 160 - Inflammation 161 - Individual treatment 162 - Inhalant allergy 162 - Inhalant antigens 162 - Inhalative allergens 163 - Inhibition mediator release assay 164 - Innate 164 - Innate and adaptive response 164 - Innate lymphoid cells 164 - Insect 164 - Insect allergy 165 - Insect venom allergy 165 - Insurance 167 - Intra-cervical lymphatic immunotherapy 167 - Intralymphatic 167 - Intralymphatic immunotherapy 167 - Intratonsillar immunotherapy 168 - IT 168 - Japanese cedar 168 - Justice 168 - KIT p.D816V 169 - Lactic acid bacteria 169 - LAR 169 - Late phase 169 - Latex 169 - Legislation 170 - Lepidoglyphus destructor 170 - Leptin 170 - Leukotriene 171 - Likelihood ratios 171 - Linear epitopes 172 - Lipocalin 2 173 - Lipid transfer proteins 173 - Local allergic asthma 173 - Local allergic rhinitis 173 - Local nasal immunotherapy 173 - Local reaction 174 - Lolium perenne 174 - Long-term effectiveness 174 - Long-term efficacy 174 - Long‐term 174 - Long‐term benefit 174 - Long‐term effect 174 - Low-dose OIT 174 - Lupus 174 - Lymph node 174 - Lymphocyte 175 - Lysosomal-associated membrane protein (LAMP) 175 - Machine learning 175 - Mechanisms 176 - Maintenance dose 176 - Major allergen content 177 - Management 177 - Mannan 177 - Mannan conjugate 177 - Manufacturing process 178 - Markov process 178 - Mast cell 178 - Mastocytosis 179 - Maximum extract concentrations safety 179 - Mechanism of action 180 - Mediators of change 180 - Medical and symptom score 180 - Medication score 181 - Meta-analysis 181 - Metabolic and epigenetic rewiring 181 - mHealth 182 - Microbiome 182 - Microcrystalline tyrosine 183 - Microbiota 183 - MicroRNA 183 - Milk 183 - Milk allergy 183 - Milk ladder 183 - Mites 184 - Modular vaccines 185 - Molecular allergens 185 - Molecular allergology 186 - Molecular allergy diagnosis 187 - Marketing authorization 187 - Molecular diagnosis 188 - Molecular reactivity profile 188 - Monitoring 188 - Monoclonal mast cell activation syndrome 188 - Monosensitized 189 - Monophosphoryllipid a 190 - miRNA 190 - Mouse models 190 - mRNA vaccines 191 - Multi-allergen 191 - Multicenter trial 191 - Nanobody 191 - Nanoparticles 191 - Nasal administration 191 - Natural history 191 - Natural tolerance 192 - Nasal allergen challenge 192 - Nasal corticosteroids 192 - Nasal mucosa 192 - Nasal polyposis 192 - Nasal provocation 193 - Nasal secretions 193 - Natural protection 193 - Network analysis 193 - Neutralizing antibody 194 - Non-allergic rhinitis 194 - Non-maleficence 194 - Non-specific lipid transfer protein 195 - Nonrandomized studies 195 - Novelty 195 - Nut allergy 195 - Nutrition 196 - OAS 196 - Observational study 196 - Occupational anaphylaxis 196 - Occupational rhinitis 196 - OIT 196 - OIT maintenance patterns 197 - Oligonucleotide therapy 198 - Olea 198 - Olive 199 - Omalizumab 199 - One‐strength dose escalation scheme 199 - Outcome measurement 200 - Oral allergy 200 - Oral allergy syndrome 200 - Oral food challenge 201 - Oral food desensitization 202 - Oral immunotherapy 203 - Oral immunotherapy trials 203 - Oral peanut challenge 203 - Oropharyngeal symptom 203 -Oral immunotherapy (OIT) 204 - Otitis 204 - Ovomucoid 204 - Oxygen therapy 205 - Paediatric 205 - Paediatric population 205 - Pan-allergen 205 - Pandemics 205 - Partially hydrolyzed formula 205 - Passive immunotherapy 205 - Pathogenic mechanisms 206 - Patient preferences 206 - Patient preparation 206 - Patient selection factors 206 - Patient-relevant benefit 206 - Patient-reported outcome measures 206 - Patient-reported outcomes 206 - Patients profiling 207 - Peanut 207 - Peanut (Arachis hypogaea) allergen powder 208 - Peanut allergy 208 - Peanut oral immunotherapy 208 - Peanut protein 208 - Peanut‐specific IgE 209 - Paediatric OIT 209 - Peach 209 - Pediatric 209 - Pediatric patients 209 - Pediatric rhinitis 210 - Peptide 211 - Peptide array 212 - Peptide immunotherapy 213 - Peptide microarrays 213 - Peptide-based vaccine 213 - Peptide-carrier vaccine 213 - Personalised immunotherapy 213 - Personalized medicine 213 - Pet dander 213 - PFAS 213 - PFAS management 213 - Phage display 213 - Pharmacotherapy 213 - Phase 1 213 - Phleum pratense 213 - Precision dosing 213 - Precision medicine 213 - Prediction 213 - Predictive modelling 213 - Prescription 213 - Prevention 213 - PROM 213 - PROMs 213- Perennial 214 - Poaceae 214 - Pollen allergy 214 - Pollen-food allergy syndrome 215 - Polistes dominulus 215 - Pollen allergy 215 - Pollen food syndrome 215 - Pollen season 215 - Polyallergy 215 - Polymerized allergoid 215 - Polymerized extracts 215 - Polysensitized 215 - Pooled analysis 215 - Post-marketing survey 215 - Post‐authorisation safety study 216 - Precision medicine 217 - Prediction 217 - Preschool children 218 - Prevention 219 - Prick skin test 219 - Primary prevention 219 - Probiotic 220 - Polistes 220 - Polymerized 220 - Polysensitisation 220 - Precision medicine 220 - PreS 220 - Prognosis 221 - Probiotic; remission 221 - Product comparability 221 - Prognostic 222 - Progression 223 - Protein transfer vector 224 - Provocation tests 225 - PQ Grass 225 - Psoriasis 225 - Psychosocial 225 - pSYK 226 - Pulmonary function 226 - Purified natural der p1 and 2 226 - QALY 227 - Quality 227 - Quality control 228 - Quality of life 229 - Questionnaire 230 - Post‐treatment 230 - Racial disparities 230 - Ragweed allergy 230 - Ragweed pollen 231 - Randomized clinical trial 231 - Randomized controlled trial 232 - Randomized dose-ranging trial 233 - Reactive dose 234 - REACT 234 - Real life 235 - Real-word 235 - Real-world evidence 235 - Real‐world analysis 235 - Real‐world data 236 - Recombinant allergen 237 - Recombinant food allergens 238 - Registry 238 - Regulatory 238 - Regulatory B cells 238 - Regulatory T cell 239 - REMA 239 - Remission 239 - Remission of allergy 239 - Remodeling 239 - Research gaps 239 - Respiratory allergy 239 - Retrospective cohort study 240 - Rhinitis 240 - Rhinitis control 240 - Rhinitis management 240 - Rhinitis questionnaires 240 - Rhinitis symptoms 240 - Rrhinosinusitis 241 - Rhinoconjunctivitis 242 - Risk factors 242 - Risk mitigation 242 - Risk reduction 243 - Risk/benefit analysis 243 - RNA sequencing 243 - rPrup3 243 - RQLQ 243 - RQLQ domains 243 - Rush immunotherapy 243 - Saline 243 - Saliva 243 - Urticaria 244 - Safety 244 - SCIT 244 - Screening 245 - Seasonal 245 - Seasonal allergic rhinitis 246 - Seasonal allergy 247 - Secondary prevention 247 - Sensitization 248 - Sequencing 249 - Sever food allergy 249 - Severe asthma 249 - Severe combined immunodeficiency 249 - Severe COVID-19 249 - Severe systemic sting reactions 249 - Severity 249 - Shellfish 250 - Shared decision-making 250 - Single highest tolerated dose 251 - Side effects 251 - Sinusitis 251 - Sinusitis control 251 - Sinusitis management 251 - Sinusitis questionnaires 251 - Sinusitis symptoms 251 - SIT 251 - Small airway dysfunction 252 - Skin 252 - Skin prick test 252 - SLIT tablet 253 - SLIT 253 - Stinging Hymenoptera 254 - Socioeconomic 254 - Socioeconomic status 255 - Solicit 256 - Specific IgE 257 - Specific immunotherapy 258 - Specific oral tolerance induction 259 - SPIREs 260 - SQ tree‐SLIT‐tablet 260 - ST-2 260 - Standardization methods 261 - Standardized quality 261 - State-transition model 261 - Stinging 261 - Study quality 262 - Subcutaneous 262 - Subcutaneous allergen immunotherapy 263 - Subcutaneous immunotherapy 264 - Subcutaneous injection 264 - Subcutaneous specific immunotherapy 265 - Sublingual 265 - Sublingual administration 265 - Sublingual immunotherapy 265 - Sublingual immunotherapy tablets 265 - Sublingual immunotherapy/adverse effects 266 - Surrogate decision making 266 - Sustained response 266 - Sustained unresponsiveness 267 - Systematic review 267 - Systems biology 268 - Symptom 268 - Symptom and medication score 268 - Symptom score 268 - Symptom severity 268 - Systemic mastocytosis 268 - Systemic reactions 269 - T cell 269 - T cell proliferation 269 - T cell response 269 - T helper 2 cells 269 - T-cell epitope 270 - Tablet 270 - Telemedicine 270 - Terminology 271 - Testing 271 - Tetanus toxoid 271 - Th2 cytokines 271 - Th2A cells 272 - Therapy 273 - Threshold 273 - Thymic stromal lymphopoietin 274 - Timothy grass pollen 275 - Tolerability 276 - Tolerance 277 - Tolerance induction 277 - Topical steroids 277 - Total combined rhinitis score 277 - Total IgE 278 - Trained immunity‐based allergen vaccines 278 - Trained immunity‐based vaccines (TIbV) 278 - Trained immunity. 278 - Transcriptome 278 - Transcriptomic 278 - Transcutaneous immunotherapy 278 - Transient response 278 - Treatment 278 - Treatment adherence 278 - Treg 279 - Treatment compliance 279 - Treatment goals 279 - Tree nuts 280 - Tree nut allergies 280 - Tree pollen allergy 281 - Trial design 282 - Trigger 282 - Tropomyosin 283 - Tryptase 283 - Tryptase genotyping 284 - Type 2 biomarker 284 - Type 2 cytokines 284 - Type 2 inflammation 284 - Type 2 innate lymphocytes 284 - Ultrafast regimen 284 - Ultrasound 284 - Universal 284 - Urban 284 - Urticaria 284 - Vaccination 284 - Vaccines 284 - Validated survey 285 - Venom 285 - Venom allergy 285 - Venom immunotherapy 286 - Vespa crabro 287 - Vespula 287- Vespula vulgaris 288 - Vestibular 288 - VHH 288 - Virus-like particles 288 - Wasps 288 -Viaskin 289 - Whole saliva 290 - Yellowjacket 291 - Allergic symptom 292 - Mindsets 293 - Patient experience 294 - T cell response 295 - Facilitated allergen presentation 296 - Super-crosslinking 297 - Tree pollen 298 - Total combined score 299 - Milk allergy 300 - Treatment outcome 301 - Biologic therapy 302 - Modified proteins 303 - Treatment 304 - Honey-bee 305 - Paper wasp 306 - Ultra-rush 307 - Wasp 308 - Multi-allergen 309 - Minimally clinical important difference 310 - Psychometric 311 - Reliability 312 - Responsiveness 313 - Score 314 - Validation 315 - Auto-injectors 316 - Informatics 317 - NLP 318 - Aseptic 319 - Compounding 320 - Infection 321 - Influenza 322 - Posts 323 - Preparation 324 - Shot 325 - Vaccination 327 - Alt a 1 328 - Fungal allergy 329 - Molecular immunotherapy 330 - Purified allergen 331 - Wallnut 332 - European Medicines Agency 333 - European Union 334 - Food and Drug Administration 336 - Extracts 337 - Practices 338 - Regulatory 339 - Sublingual 340 - IgE tests 341 - Diagnostic algorithm 342 - Molecular spreading 343 - Follicular helper T cells 344 - Regulatory B cell 345 - Microbial adjunct 346 - Microbiome 347 - Microbiota 348 - Oral tolerance 349 - Prebiotics 350 - Probiotics 351 - Ocular allergy 352 - Allergic conjunctivitis 353 - Viaskin® Peanut 354 - Allergic disease 355 - Adults 356 - AIT 357 - Fungal vaccines 358 - ACE-inhibitor 359 - Autoimmunity 360 - Beta-blocker 361 - Contraindications 362 - Malignancy 363 - Pregnancy 364 - Venom hypersensitivity 365 - Environmental Exposure Unit 366 - Fatality 367 - Systemic allergic reactions 368 - Cluster immunotherapy 369 - Conventional immunotherapy 370 - Inhaled corticosteroid 371 - Adoptive transfer 372 - Mepolizumab 373 - Basophil 374 - Anti-Fel d1 IgY 375 - Fel d 1 376 - Low allergen cookies 377 - Inhalants 378 - Patients 379 - Recommendations 380 - Sensitization 381 - History 382 - Perspectives 383 - Dendritic cells 384 - Human 385 - Mast cells 386 - Adrenaline 387 - Venom allergy 388 - Young adults 389 - Hazelnut 390 - Experimental models of disease 391 - Molecular medicine 392 - Cytokines 393 - LAIS 394 - Staloral 395 - Allergen exposure chamber 396 - Novel therapy 397 - Accelerated dose escalation 398 - Side effects 399 - B cell 400 - Memory B cell 401 - Plasmablasts 402 - Treatment initiation 403 - Sting challenge 404 - Three-day rush protocol 405 - Field re-sting 406 - Tyrosine adsorbed 407 - Exercise-induced allergic reaction 409 - Wheat allergy 410 - Accidental exposure 411 - Drops 412 - Tablets 413 - Atopy 414 - Biologic 415 - Dupilumab 416 - Mal d 1 417 - Oral allergy syndrome 418 - SCIT 419 - QALY 420 - Blocking antibodies 421 - Recombinant derivatives 422 - Artemisia annua 423 - Trade-off 424 - Values clarification 425 - IgE-blocking factor 426 - allergen-specific IgE 427 - Basophil activation test 428 - Basophil sensitivity measurement 429 - Facilitated antigen binding 430 - AD atopic dermatitis 431 - BA bronchial asthma 432 - CM cow’s milk 433 - CM-Avoid complete milk avoidance 434 - Ca, calcium 435 - Diet 436 - HtSDS, height standard deviation scores 437 - IgE, immunoglobulin E 439 - SD, standard deviation 440 - SDS, standard deviation scores 441 - ΔHtSDS, difference in height standard deviation score between the start and end of the observation period 442 - Clinical practice guidelines 443 - Ethics 444 - Evidence 445 - Indication 446 - Multi-criteria decision analysis 447 - Patient-centered 448 - Japanese cedar pollinosis 449 - Solid-in-oil nanodispersions 450 - Transcutaneous immunotherapy 451 - Asthma exacerbation 452 - SLIT-tablet 453 - Eczema 454 - Epidemiology 455 - Food allergy management 456 - Pathogenesis 457 - IgG1 458 - IgG2 459 - IgG3 460 - IgG subclass 461 - Allergen microarray 462 - Recombinant allergens 463 - ALK, Denmark-based pharmaceutical company 464 - BIOCEN, National Center of Bioproducts 465 - BU, Biological Units 466 - BU/mL, Biological units per milliliter 467 - Blo t, Mayor allegen of Blomia tropicalis 468 - Bt, Blomia tropicalis or B. tropicalis 469 - CECMED, Center for State Control of Drugs, Equipment and Medical Devices 470 - Ch10, Allergen specific reactivity calculated relative to the Histamine HC 10 mg/mL 471 - Dp or D, pteronyssinus: Dermatophagoides pteronyssinus 472 - Ds or D, siboney: Dermatophagoides siboney 473 - HDM SCIT, Immunotherpy Subcutaneous with allergens of House Dust Mite 474 - HDM, House Dust Mite 475 - OCI, Overall clinical improvement 476 - PEF, Peak Expiratory Flow 477 - Standardized allergen extract 478 - VALERGEN-BT, Standardized allergen extract of Blomia tropicalis 479 - SM, Symptom and Medication 480 - SMD, Standard Mean Difference 481 - Epinephrine use 482 - Peanut oral immunotherapy 483 - Systemic reaction 484 - Pollen 485 - Parietaria judaica 486 - Parietaria officinalis 487 - Parietaria pollen 488 - Allergens 489 - Allergoids 490 - Monomeric allergoids 491 - Molecular allergy vaccines 492 - preventive effects 493 - Anti-IgE 494 - Randomized controlled trial 495 - COVID-19 496 - Cost-effectiveness analysis 497 - Economic outcomes 498 - Epinephrine autoinjectors 499 - Quality-adjusted life-years 500 - SARS-CoV-2 501 - Simulation 502 - Systemic reaction to immunotherapy 503 - angioedema 504 - personal protective equipment 505 - Primary immunodeficiency 506 - Urticaria 507 - ILIT 508 - Intralymphatic 509 - Cedar 510 - Intranodal 511 - Subcutaneous route 512 - Sublingual route 513 - EREFS 514 - EoEHSS 515 - Inflammation 516 - Immune regulation 517 - Dual allergic rhinitis 518 - Endophenotypes 519 - Local allergic asthma 520 - Local respiratory allergy 521 - Allergen-IgE 522 - Cat dander 523 - Immunogenicity 524 - Allergy clinic 525 - Position paper 526 - Psychological COVID 527 - Biomarkers 528 - Baked egg 529 - Extensively heated egg 530 - Paediatric Committee (PDCO) 531 - Paediatric Investigation Plan (PIP) 532 - Therapy Allergen Ordinance (TAO) 533 - Immunomodulation 534 - Mesenchymal stem cells 535 - Oral food challenge test 536 - Child 537 - Core outcome 538 - Patient reported outcomes 539 - Clinical response measurements 540 - Combined symptom medication score 541 - Ultrasound guided injections 542 - Allergies 543 - Egg allergens 544 - Mobile health 545 - E-diary 546 - Digital 547 - Metabolomics 548 - Transcriptomics 549 - Api m 10 550 - Api m 6 551 - Component-resolved diagnostics 552 - Venom sensitization profile 553 - Veterinary 554 - Cluster protocol 555 - Rush protocol 556 - Ultra-rush protocol 557 - FAQLQ 558 - food allergy quality of life 559 - patient-centered outcomes 560 - Cell biology 561 - Clinical trials 562 - Emergency room 563 - Tolerated dose 564 - CD4 + T cell 565 - OIT 566 - RNAseq 567 - Single cell 568 - Medication score 569 - Symptom score 570 - Allergen intradermal immunotherapy 571 - Grass allergy 572 - Paediatrics 573 - Poaceae 574 - Omics 575 - Personalized medicine 576 - Treatable traits 577 - Asthma phenotypes and endotypes 578 - Innate lymphoid cells 579 - Allergy diagnosis 580 - Venom allergen 581 - Venom-specific immunotherapy 582 - Follicular regulatory T cell 583 - US Food and Drug Administration 584 - Yogurt cultures 585 - Lactobacillus plantarum 586 - Bifidobacterium lactis 587 - Cow’s milk allergy mouse model 588 - Outcome measures 589 - Bronchial allergen challenge 590 - Sublingual allergen immunotherapy 591 - Follow-up 592 - Immunoglobulin G4 593 - Allergic reactions 594 - Dosing regimens 595 - Basal tryptase concentration 596 - Bee venom 597 - Bee venom allergy 602 - Male 603 - Millilitres 604 - Number of patients 606 - Microlitres 607 - Female 608 - Innate and adaptive immune response 609 - T cells 610 - Basophil activation tests 611 - Food oral immunotherapy 612 - Skin prick tests 613 - Periostin 614 - Rhinoconjunctivitis Quality of Life Questionnaire 615 - Clinical presentations 616 - Equine hypersensitivity 617 - Horse aeroallergens 618 - Prevalence Abortion Accelerated Accidental exposure Accuracy ACE2 Receptor Actair Adaptive immunity Adenotonsillar disease Adjuvant effect Adjuvants Administration Administration routes Adverse events Adverse reaction Adverse reactions Aeroallergens and food allergens Aerobiology AGREE II AI-based chatbots AI-based tools Airway hyperresponsiveness Airway inflammation Airway resistance AIT AIT efficacy Allergen Allergen avoidance Allergen exposure chambers Allergen homologous groups Allergen immunotherapy (AIT) Allergen molecules Allergen presentation platforms Allergen regulation Allergen threshold Allergen-immunotherapy Allergen-specific immunotherapy Allergen‐specific immunotherapy Allergic Allergic airway inflammation Allergic asthma Allergic diseases Allergic pediatric patients Allergic reaction Allergic rhinitis Allergic rhinoconjunctivitis Allergy Allergy desensitization; Allergy testing ALR Aluminium Anaphylatoxin C3a and C5a Anaphylaxis Animal immunotherapy Animal model Antigen specific T cells Antihistamine Antihistamine premedication Antiviral immunity Anxiety APC Apple Apps AR101 Ara h 2 ARIA Artemisia vulgaris Artificial Intelligence Artificial Intelligence (AI) ASP0892 ASP2390 Asthma Asthma management Asymptomatic Atopic asthma Atopic dermatitis Atopy AXL B cells B-lymphocytes regulatory B‐cell epitopes B‐lymphocyte cell Bacteroidota Baked egg allergy Baked milk Baked milk allergy BAMSE Baseline serum tryptaste Basophil activation test Basophil activation test nonresponders Basophilis Basophils Bee Bee venom immunotherapy Beta-blockers Bioinformatics analysis Biological Biological markers Biological therapy Biologicals Biologics Biomarker Biomarkers Biomaterials Birch pollen food allergy syndrome Blattella germanica Blocking antibodies brain-derived neurotrophic factor (BDNF) Bronchial epithelium Bronchial hyperresponsiveness Build up Burden Butyrate-producing bacteria Buzzy device CAP-inhibition Carbamylated monomeric allergoid Cardiovascular disease Caregiver proxy Casein Catch-Up Growth Causal inference CD38+TH2A CD8+ T cells Characteristics Children and adults Chronic rhinosinusitis Circular chemistry Climate change Clinical effects Clinical immunology Clinical response Clinical study Cluster Codfish allergy Cofactor Cofactors Cohort study Combination therapy Comparison Compliance Component Component‐resolved diagnostics Computer simulation Congenital abnormalities Coronavirus disease 2019 Corticosteroid Cost-minimization Costs and cost analysis COVID-19 Cow milk Cow milk allergy Cow’s milk Cow’s milk allergy Cow’s milk proteins CRD CRITICAL Cross-reactivity CTLA-4 Cytokine Cytokine Expression DBPCFC Delayed introduction Delphi method Denmark Der p 1 Der p 2 Der p1 Der p2 Der p23 Dermatophagoides Desensitization Desensitization therapy Determinants Diet Differentially expressed genes Digital health Directive 2001/83/EC Discontinue treatment Discrete choice experiment Disease-modifying effect DNA methylome Dose adaptation Double allergy Dual allergic rhinitis Dupilumab EAACI EAACI CSMS0–6 Economic evaluation Education Effector function Efficacy prediction Efficacy variability Efficacy; Egg hypersensitivity Egg ladder Eliciting dose Entomopathogens Eosinophilic esophagitis scoring systems Eosinophils Epicutaneous immunotherapy Epidemiology Epigenome‐wide DNA methylation study Epinephrine EPIT Epithelial barrier theory Epitope profiling EQ-5D-5L Esophageal eosinophilia EU data Euroline® European Pharmacopoeia Eustachian tube dysfunction Evaluation Evidence Exotic animal allergy Exposome FAQLQ-PF Fatty acid oxidation FcεRI Fel d 1 Field sting Food (allergen) tolerance Food allergy Food allergy diagnostics Food allergy immunotherapy Food allergy related quality of life Food hypersensitivity Gaps in therapy Genomics Glutaraldehyde-polymerized extracts Grass Immunotherapy Grass pollen allergy Grass-specific T cells Gut microbiota Gut–skin axis HDM Health economics Health-related quality of life Healthcare Healthcare cost Hen’s egg allergy Histone modification HLA Honeybee vemon allergy Honeybee venom House dust mite‐sensitization Hydrogel Hymenoptera Hymenoptera venom allergy Hymenoptera venom-induced anaphylaxis IgA 1 IgA 2 IgA memory B cell IgE IgE binding avidity IgE blocking activity IgE monoclonal antibodies IgE-FAB IgE-mediated IgE-mediated food allergy IgG blocking antibodies IgG monoclonal antibodies IgG4 IL-17A IL-36γ ILC2 Immune cell subsets Immune metabolism Immune response Immune system Immunity ImmunoCAP® Immunoglobulin Immunologic Immunologic desensitization Immunologic response Immunological biomarkers Immunotherapy Immunotherapy and tolerance induction Immunotherapy clinical Immunotherapy vaccines and mechanisms In vitro sIgE testing Indirect comparison Induced sputum Inflammation Informed consent Inhibitory receptor Innate immunity Innate lymphoid cells Innovations Interleukin-10 Intraddermal test Intradermal test Investigator’s Global Assessment Japanese cedar pollinosis JMDC claims database Kashmir (India) Labeling LAD2 LAMP-based DNA vaccine LAR Laundry detergent Lipid transfer protein lncRNA Local immune signature Long-term effect Long-term efficacy Low dose Low-dose Lung function Macrophage Macrophage migration inhibitory factor Maintenance intervals Major allergen Mapping Markov model MASK-air® Mast cell activation syndrome Mast cell activation test Mast cell disease Mastocytosis Matrix metalloproteinase-9 Mechanisms Mechanisms of action Medications Medium dose MER Meta-analysis; omalizumab Metabolism Metabolites Methacholine challenge test Methods Methylation mHealth Microarray Microbial diversity Microbiome Microcrystalline tyrosine-adsorbed allergoids Microneedle Microneedles MicroRNAs Milk allergy Milk ladder Minimal important difference Mite allergy Moderate to severe allergic asthma in children Molecular components Molecular diagnosis techniques Molecular diagnostics Molecular reactivity profiling Molecular sensitization pattern Molecular standardization Monomeric allergoid Monosensitization Moulds Mucosal Mucosal‐associated invariant T cells Multiallergen treatment Multicenter study Multifood allergy Multimer positive T cells Multiomics Multiple allergen immunotherapy Multiple-food oral immunotherapy NAC Nanomaterials Nanoparticle delivery systems Nanovaccine Nasal allergen responses Nasal cytology Nasal mucosal delivery Nasal surface Nasal surgical procedures Nasal swabs Native allergen purification Network meta-analysis Neutrophil Nitric oxide NK cells NO Nomogram Novel vaccines NPP Nutraceuticals Occupational lung disease Odds ratio Ole e I protein Ole e VII protein OLE9 protein Olea europaea Olive pollen Omalizumab dosage Open-label study Oral Oral cavity Oral food challenge Oral immunotherapy Oral immunotherapy induced gastrointestinal eosinophilic reaction Oral microbiota Otitis Otitis media Outcomes Overview of systematic reviews and meta analyses Ovomucoid-specific IgE Ovomucoid-specific IgG4 Oxidative phosphorylation Paediatric allergy Pain interventions Pan-allergen Parents Passive allergy immunotherapy Patient adherence Patient education Patient outcomes Patient preferences Patient safety Patient's benefit PD-1 Peach Peanut (Arachis hypogaea) allergen powder-dnfp Peanut allergy Peanut oral immunotherapy Peanut Specific IgG4 Peanut-specific IgE Peanut. Pediatric food allergy Pediatric Growth Pediatric respiratory allergy Pediatrics Penetration enhancers Personalised medicine Personalized immunotherapy Personalized medicine Pet allergy Phenolic compounds Phenotype Phenotypes Phospholipase A1 pivotal Phase III clinical trial Pivotal phase III trial Placebo effects Placebo-crossover Pol d 1 Pol d 5 Polistes Polistes dominula Pollen Pollen exposure Pollen season Pollen-induced allergic rhinitis Pollyallergic Polysensitization Precision dosing Precision medicine Prediction model Predictive biomarkers Predictive model Predictive value Premature birth Preseason Prick test Proallergric TH2 Probiotics PROMs Propensity score matching Prostaglandin E2 Proteomics Protocols Pru p3 sublingual immunotherapy PS/QI PTAH QALY Quality improvement Quality of Life Questionnaire Quality of life questionnaires Quality requirements Questionnaire Questionnaires Random forest Randomized controlled trials REACT Reaction severity Reaction threshold Reactions Real-life evidence Real-life settings Real-life studies Real-life study Real-word Real-world Setting. Real-world study Real‐world evidence Recombinant Regression Regulatory T cells RELEVANT Respiratory allergy Response Review Rhinitis Risk factor Risk factors RNA RNA sequencing ROC curve Routinely collected Health Data S100A11 Safe dose Safe dosing rules Safety SCIT SCORing Atopic Dermatitis Sensitization Sensitization profile Sesame allergy Severe Asthma Severity Severity score SF-6Dv2 Shared decision-making Short-course treatment ShotBlocker SIgE/sIgG4 ratio Single cell RNA-Seq Skin patches Skin prick test SLIT SLIT-liquid Specific IgG4 Specific Immunoglobulin E Specific immunotherapy SQ SLIT tablet Sting challenge test Subcutaneous Allergen Immunotherapy Subcutaneous immunotherapy Sublingual and buccal mucosae Sublingual immunotherapy Sublingual immunotherary tablet Surgery Sustained response Sustained unresponsiveness Symptom score Symptomatic drugs Symptoms in allergic rhinitis Systematic review Systematic reviews Systemic Systemic adverse events Systemic reaction T cell epitopes T cells T-cell exhaustion TAM receptor tyrosine kinases Target maintenance dose Targeting oral dendritic cells Taurolithocholic acid TCR repertoires Technical standards Technology Tfh cells Th2 Th2 cells Th2 response The symptoms after COVID-19 infection Therapy Allergen Ordinance (TAO) Thrombin-activatable fibrinolysis inhibitor Tolerogenic response Toll-like receptor agonists Tooth eruption Toxicokinetic Transcriptome Transdermal delivery Transdermal immunotherapy Translation Treatment Treatment hierarchy Treatment monitoring Treatment strategy Tree-nut allergy Trial design Tropomyosin Type 2 inflammation Type 2 memory B cells TYRO3 Ultra-short course Undiluted mixtures Utility Vaccine Venom Verrucomicrobiota Ves v 5. Vespid Vespula spp. Viaskin Peanut Viral infection VIT Vitamin D Waiting Times Warburg Wasp venom Wastage Web Work-up World allergy organization α-lactalbumin β-lactoglobulin
